

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
WO 03/072713 A2

- (51) International Patent Classification<sup>7</sup>: C12N
- (21) International Application Number: PCT/US03/05147
- (22) International Filing Date: 21 February 2003 (21.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/358,427 21 February 2002 (21.02.2002) US
- (71) Applicant (for all designated States except US): BIO-GEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KALLED, Susan, L. [US/US]; 100 Elsinore Street, Concord, MA 01742 (US).

REID, Hugh [AU/AU]; Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800 (AU).


(74) Agent: GARRETT, Arthur, S.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, NW, Washington, DC 20005-3315 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,

[Continued on next page]

(54) Title: USE OF BCMA AS AN IMMUNOREGULATORY AGENT



(57) Abstract: The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF.



SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- without international search report and to be republished upon receipt of that report